Robocath has already succeeded in raising a total of €1.8 million in 2013 and 2015, to which Bpifrance and others added €1.6 million of public aid.
Currently at the manufacturing stage and in the process of obtaining the CE mark, the company’s first robotic platform, the R-one, represents a major step forward in interventional cardiology. By improving patient care and drastically reducing physicians’ exposure to X-rays, which currently cause some serious diseases, R-one benefits the whole health care system.
In practice, this fully integrated robotics platform covered by 20 families of international patents allows physicians to manage their instruments remotely from a control panel close to the operating table. It is a sophisticated tool based on two major technologies: R-grasp, which exactly reproduces hand movements (rotation and simultaneous movement), and SecurAccess, which provides stability and security during the medical procedure. The R-one platform has already earned some very promising feedback, primarily thanks to its ease-of-use. The fast-growing global market for the device is worth an estimated €4.5 billion.
Philippe Bencteux, chairman and founder of Robocath, said: “The whole team and I would like to thank our historical shareholders, Go Capital and NCI, for their renewed support, our bank partners BNP Paribas and La Caisse d’Epargne, and our new institutional shareholders for their strong buy-in to our plans. This new funding will help us to achieve a decisive milestone in our development strategy. R-one is currently the only robotic assistance platform for interventional cardiology developed in Europe. We plan to build on this technological edge to enter the European market next year. Given our many strengths, we will also continue to design sophisticated robotics solutions, helping to usher in a new era of medicine to benefit physicians and patients.”